Merck,MK-2870-019, Ph3, Open label randomized, Pembrolizumab +/- MK-2870 , NSCLC

What is the Purpose of this Study?

Primary Objective: Objective: To compare MK-2870 plus pembrolizumab versus pembrolizumab monotherapy with respect to DFS as assessed by BICR. DFS: the time from randomization to any recurrence (local, locoregional, regional or distant), occurrence of new primary NSCLC, or death due to any cause, whichever occurs first. Secondary Objective: Objective: To compare MK-2870 plus pembrolizumab to pembrolizumab monotherapy with respect to OS. OS: The time from randomization to death due to any cause


Eligibility

  • * Has histological or cytological confirmation of squamous or nonsquamous non-small cell lung cancer (NSCLC), resectable clinical Stage II, IIIA or IIIB (with nodal involvement \[N2\]) per AJCC eighth edition guidelines.
  • * Has confirmation that epidermal growth factor receptor (EGFR)-directed therapy is not indicated as primary therapy.
Show more

Where can I participate?

  • CS Cancer at Cedars-Sinai Medical Center : Garrett Crook
  • CS Cancer at The Angeles Clinic and Research Institute : Garrett Crook


More about this Clinical Trial

What is the full name of this clinical trial?

MK-2870-019: A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab with or without MK-2870 in Respectable Stage II to IIIB NSCLC for Participants not Achieving pCR after Receiving Neoadjuvant Pembrolizumab with Platinum based Doublet Chemotherapy Followed by Surgery

Study Details
Disease Type/Condition

Lung

Principal Investigator

Sankar, Kamya

Co-Investigators

Cathie T Chung, Harmik J Soukiasian, Inderjit Mehmi, Justin Moyers, Karen Reckamp, Kristopher Wentzel, Mark Faries, Navid Hafez, Omid Hamid, Vi K. Chiu

Age Group

Adult

Phase

III

IRB Number

STUDY00003272

ClinicalTrials.gov ID

NCT06312137

Key Eligibility
ClinicalTrials.gov

How do I learn more about this study?
Name

Garrett Crook

Email
Garrett.Crook@cshs.org
Study Detail
Disease Type/Condition

Lung

Principal Investigator

Sankar, Kamya

Age Group

Adult

Phase

III

IRB Number

MK-2870-019

ClinicalTrials.gov ID

NCT06312137

Key Eligibility
ClinicalTrials.gov

Contact
Name

Garrett Crook

Email
Garrett.Crook@cshs.org